Biodefense Market Size By Product (Vaccines, Biothreat Detection Devices), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022- 2028

Description

List of Tables

The biodefense market is anticipated to grow substantially by 2028 on account of increasing government initiatives for promoting treatment strategies to develop effective vaccines to combat mutated vaccines as well as detection devices against biothreats. Biodefense refers to measures taken against bioterrorism, which involves the deliberate release of organisms and fatal viruses.

In recent years, governments across the globe have taken various initiatives to instill biodefense mechanisms against bioterrorism. Biothreats not only harm human health but also human resources, which impacts the economic growth of a country. Notably, the COVID-19 pandemic has prompted innovations in the development of vaccinations and biothreat detection devices.

To that effect, in October 2021, the World Health Organization (WHO) called for a change in diagnostics globally to fill the biodefense gap created between LICs (low-income countries) and developed nations, following the launch of the Test-to-Treat initiative by U.S. President Biden, which offers free treatment and testing kits to all American citizens who test positive. As a result, supportive government initiatives for formulating innovative biodefense solutions have been beneficial for biodefense industry growth.

Furthermore, key players in the sector have been investing in consistent improvement and technological advancements in biodefense mechanisms, thereby fostering biodefense market outlook. To cite an instance, in March 2022, Bavarian Nordic, a major biotechnology firm, inked a license & supply deal with Nuance Pharma, a China-based pharmaceutical company. The agreement was undertaken to facilitate the development as well as commercialization of MVA-BN RSV, Bavarian Nordic's vaccine candidate that targets respiratory syncytial virus (RSV) in older adults.

In another instance, in October 2021, Smiths Detection Group Ltd., a leading enterprise in threat detection and security screening tech, announced that its air sampler BioFlash Biological Identifier device is capable of detecting SARS-CoV-2 variants. The air sampler was successfully utilized by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) as well as many universities to curb the spread of COVID-19.

The biodefense market has been segmented based on product and region. Based on product, the market has been further classified into biothreat detection devices and vaccines. The vaccines product segment was valued at more than USD 10 billion in 2021 and is projected to showcase strong growth through the review timeline. Increased emphasis of research activities on the development of new vaccine technologies, including vector technology, to induce rapid protection against pathogen attacks is slated to fuel segmental growth.

In the regional landscape, the Latin America biodefense market is estimated to depict a growth rate of about 8.9% CAGR over 2022-2028. Favorable government initiatives to strengthen biosecurity and growing investments in biodefense products across LATAM are foreseen to promote regional industry growth in the forthcoming years.

Product Code: 714

Chapter 1 Methodology

1.1 Methodology
1.2 Market definitions
1.3 Forecast parameters
1.4 Data sources
- 1.4.1 Secondary
  - 1.4.1.1 Paid sources
  - 1.4.1.2 Unpaid sources
- 1.4.2 Primary

Chapter 2 Executive Summary

2.1 Biodefense industry 360 degree synopsis, 2017 - 2028
- 2.1.1 Business trends
- 2.1.2 Product trends
- 2.1.3 Regional trends

Chapter 3 Biodefense Industry Insights

3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2028
3.3 Industry impact forces
- 3.3.1 Growth drivers
  - 3.3.1.1 Technological advancements in biotechnology sector in North America and Europe
  - 3.3.1.2 Favorable government initiatives in Asia Pacific and Latin America
  - 3.3.1.3 Growing investments by government in R&D in North America & Europe
- 3.3.2 Industry pitfalls & challenges
  - 3.3.2.1 Low R&D funding by government in underdeveloped regions
3.4 Growth potential analysis
- 3.4.1 By product
3.5 COVID-19 impact analysis
3.6 Porter's analysis
3.7 Competitive landscape, 2021
- 3.7.1 Company matrix analysis, 2021
3.8 PESTEL analysis

Chapter 4 Biodefense Market, By Product

4.1 Key segment trends
4.2 Vaccines
- 4.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.2.2 Anthrax
  - 4.2.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.2.3 Smallpox
  - 4.2.3.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.2.4 Botulism
  - 4.2.4.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.2.5 Others
  - 4.2.5.1 Market size, by region, 2017 - 2028 (USD Million)
4.3 Biothreat detection devices
- 4.3.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.3.2 Samplers
  - 4.3.2.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.3.3 Detectors/triggering devices
  - 4.3.3.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.3.4 Identifiers
  - 4.3.4.1 Market size, by region, 2017 - 2028 (USD Million)
- 4.3.5 Assays and reagents
  - 4.3.5.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 5 Biodefense Market, By Region

5.1 Key regional trends
5.2 North America
- 5.2.1 Market size, by country, 2017 - 2028 (USD Million)
- 5.2.2 Market size, by product, 2017 - 2028 (USD Million)
  - 5.2.2.1 Market size, by vaccines, 2017 - 2028 (USD Million)
  - 5.2.2.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
- 5.2.3 U.S.
  - 5.2.3.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.2.3.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.2.3.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
- 5.2.4 Canada
  - 5.2.4.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.2.4.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.2.4.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
5.3 Europe
- 5.3.1 Market size, by country, 2017 - 2028 (USD Million)
- 5.3.2 Market size, by Product, 2017 - 2028 (USD Million)
- 5.3.3 Germany
  - 5.3.3.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.3.3.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.3.3.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
- 5.3.4 UK
  - 5.3.4.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.3.4.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.3.4.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
- 5.3.5 France
  - 5.3.5.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.3.5.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.3.5.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
- 5.3.6 Spain
  - 5.3.6.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.3.6.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.3.6.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
5.4 Asia Pacific
- 5.4.1 Market size, by country, 2017 - 2028 (USD Million)
- 5.4.2 Market size, by product, 2017 - 2028 (USD Million)
- 5.4.3 Japan
  - 5.4.3.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.4.3.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.4.3.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
- 5.4.4 China
  - 5.4.4.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.4.4.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.4.4.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
- 5.4.5 India
  - 5.4.5.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.4.5.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.4.5.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
5.5 Latin America
- 5.5.1 Market size, by country, 2017 - 2028 (USD Million)
- 5.5.2 Market size, by product, 2017 - 2028 (USD Million)
- 5.5.3 Brazil
  - 5.5.3.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.5.3.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.5.3.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
- 5.5.4 Mexico
  - 5.5.4.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.5.4.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.5.4.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
- 5.5.5 Argentina
  - 5.5.5.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.5.5.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.5.5.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
5.6 MEA
- 5.6.1 Market size, by country, 2017 - 2028 (USD Million)
- 5.6.2 Market size, by product, 2017 - 2028 (USD Million)
- 5.6.3 South Africa
  - 5.6.3.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.6.3.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.6.3.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
- 5.6.4 Saudi Arabia
  - 5.6.4.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.6.4.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.6.4.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)
- 5.6.5 UAE
  - 5.6.5.1 Market size, by product, 2017 - 2028 (USD Million)
    - 5.6.5.1.1 Market size, by vaccines, 2017 - 2028 (USD Million)
    - 5.6.5.1.2 Market size, by biothreat detection devices, 2017 - 2028 (USD Million)

Chapter 6 Company Profiles

6.1 Strategy dashboard, 2021
6.2 Alexeter Technologies, LLC
- 6.2.1 Business overview
- 6.2.2 Financial data
- 6.2.3 Product landscape
- 6.2.4 Strategic outlook
- 6.2.5 SWOT analysis
6.3 Altimmune
- 6.3.1 Business overview
- 6.3.2 Financial data
- 6.3.3 Product landscape
- 6.3.4 Strategic outlook
- 6.3.5 SWOT analysis
6.4 ANP Technologies
- 6.4.1 Business overview
- 6.4.2 Financial data
- 6.4.3 Product landscape
- 6.4.4 Strategic outlook
- 6.4.5 SWOT analysis
6.5 Bavarian Nordic
- 6.5.1 Business overview
- 6.5.2 Financial data
- 6.5.3 Product landscape
- 6.5.4 Strategic outlook
- 6.5.5 SWOT analysis
6.6 BioFire Defense (bioMérieux SA)
- 6.6.1 Business overview
- 6.6.2 Financial data
- 6.6.3 Product landscape
- 6.6.4 Strategic outlook
- 6.6.5 SWOT analysis
6.7 Biosearch Technologies
- 6.7.1 Business overview
- 6.7.2 Financial data
- 6.7.3 Product landscape
- 6.7.4 Strategic outlook
- 6.7.5 SWOT analysis
6.8 Bruker Detection
- 6.8.1 Business overview
- 6.8.2 Financial data
- 6.8.3 Product landscape
- 6.8.4 Strategic outlook
- 6.8.5 SWOT analysis
6.9 Electronic Sensor Technology Inc.
- 6.9.1 Business overview
- 6.9.2 Financial data
- 6.9.3 Product landscape
- 6.9.4 Strategic outlook
- 6.9.5 SWOT analysis
6.10 Elusys Therapeutics
- 6.10.1 Business overview
- 6.10.2 Financial data
- 6.10.3 Product landscape
- 6.10.4 Strategic outlook
- 6.10.5 SWOT analysis
6.11 Emergent BioSolutions
- 6.11.1 Business overview
- 6.11.2 Financial data
- 6.11.3 Product landscape
- 6.11.4 Strategic outlook
- 6.11.5 SWOT analysis
6.12 Ichor Medical Systems, Inc.
- 6.12.1 Business overview
- 6.12.2 Financial data
- 6.12.3 Product landscape
- 6.12.4 Strategic outlook
- 6.12.5 SWOT analysis
6.13 Nanologix
- 6.13.1 Business overview
- 6.13.2 Financial data
- 6.13.3 Product landscape
- 6.13.4 Strategic outlook
- 6.13.5 SWOT analysis
6.14 New Horizon Diagnostic Corp.
- 6.14.1 Business overview
- 6.14.2 Financial data
- 6.14.3 Product landscape
- 6.14.4 Strategic outlook
- 6.14.5 SWOT analysis
6.15 PositiveID Corporation
- 6.15.1 Business overview
- 6.15.2 Financial data
- 6.15.3 Product landscape
- 6.15.4 Strategic outlook
- 6.15.5 SWOT analysis
6.16 SIGA Technologies
- 6.16.1 Business overview
- 6.16.2 Financial data
- 6.16.3 Product landscape
- 6.16.4 Strategic outlook
- 6.16.5 SWOT analysis
6.17 Smiths Detection Group Ltd.
- 6.17.1 Business overview
- 6.17.2 Financial data
- 6.17.3 Product landscape
- 6.17.4 Strategic outlook
- 6.17.5 SWOT analysis
6.18 Synexis Systems
- 6.18.1 Business overview
- 6.18.2 Financial data
- 6.18.3 Product landscape
- 6.18.4 Strategic outlook
- 6.18.5 SWOT analysis